 BASEL, Switzerland and NEW YORK, Oct. 19, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV and Pfizer Inc. NYSE: PFE today announced the presentation of new data from clinical studies of its once-daily relugolix combination therapy relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg in premenopausal women with uterine fibroids and in women with endometriosis pain an investigational use. The data are being presented in oral sessions during the American Society for Reproductive Medicine ASRM 2021 Congress. 